Both authors contributed equally to this study.
Capture and generation of adenovirus specific T cells for adoptive immunotherapy
Article first published online: 8 NOV 2006
British Journal of Haematology
Volume 136, Issue 1, pages 117–126, January 2007
How to Cite
Chatziandreou, I., Gilmour, K. C., McNicol, A.-M., Costabile, M., Sinclair, J., Cubitt, D., Campbell, J. D. M., Kinnon, C., Qasim, W. and Bobby Gaspar, H. (2007), Capture and generation of adenovirus specific T cells for adoptive immunotherapy. British Journal of Haematology, 136: 117–126. doi: 10.1111/j.1365-2141.2006.06386.x
JDMC is employed by Miltenyi Biotech, and declares this as a possible conflict of interest.
- Issue published online: 8 NOV 2006
- Article first published online: 8 NOV 2006
- Received 20 December 2005; accepted for publication 19 September 2006
- cellular immunotherapy;
Adenoviral infections represent a major cause of morbidity and mortality following haematopoietic stem cell transplantation. Current anti-viral agents are virostatic and it is evident that elimination of adenovirus (ADV) infection is only achieved by recovery of cellular immunity. Using an interferon-gamma (IFN-γ) secretion and capture assay to isolate ADV-specific T cells, followed by a 2 week expansion and restimulation protocol, we generated ADV T cells that may be used for cellular immunotherapy. In contrast to virus-specific T cells for cytomegalovirus or Epstein-Barr virus, the ADV response was dominated by CD4+ T cells and the majority of captured cells exhibited an effector/memory immunophenotype. Highly specific antigen responses were demonstrated by intracellular IFN-γ expression and cytotoxicity assays when the expanded cells underwent restimulation with ADV-pulsed target cells. Although T cells were initially generated in response to ADV species C, the expanded populations also showed strong activity against ADV species B, suggesting cross-reactivity across ADV species; a finding that has important clinical consequences in the paediatric setting, where the majority of infections are caused by ADV type B and C. The protocols can be readily translated to generate ADV-specific T cells suitable for clinical use and offer an effective immunotherapeutic strategy to control ADV infection.